ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A ...
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, ...
The use of primary mesenchymal stem cells (MSCs) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSCs)-derived MSCs ...
TOKYO--(BUSINESS WIRE)--Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it ...
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a ...
Allogene Therapeutics Inc., a South San Francisco-based company developing off-the-shelf allogeneic T-cell therapies for cancer, is taking a 25% stake in Notch Therapeutics Inc., paying the Canadian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback